Quantum-Si incorporated

NasdaqGM QSI

Quantum-Si incorporated EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -88.46 M

Quantum-Si incorporated EBITDA is USD -88.46 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 21.42% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Quantum-Si incorporated EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -112.57 M, a -0.24% change year over year.
Quantum-Si incorporated EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -112.30 M, a -51.42% change year over year.
Quantum-Si incorporated EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -74.17 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: QSI

Quantum-Si incorporated

CEO	Mr. Jeffrey Alan Hawkins
IPO Date	Nov. 13, 2020
Location	United States
Headquarters	530 Old Whitfield Street
Employees	159
Sector	Health Care
Industries Biotechnology Pharmaceuticals Semiconductors

Description

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

Key trends

Past 5 years